TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm dedicated to developing advanced therapeutic platforms that tackle the root causes of diseases, rather than just managing symptoms. Its flagship drug platform, MYMD-1, is a small molecule currently undergoing clinical trials. This platform functions by modulating the immune system to regulate TNF-alpha—a key driver of chronic inflammation—and other pro-inflammatory cytokines. MYMD-1 is being developed with the potential to slow aging, extend life, and treat various autoimmune conditions. The company also boasts Supera-CBD, its second innovative platform. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD), designed to enhance and cater to the expanding CBD market, which includes both FDA-approved medications and other unregulated CBD products. Its intended uses span chronic pain relief, addiction treatment, and epilepsy. Founded in 2014, the company was initially known as MyMD Pharmaceuticals, Inc. before rebranding to TNF Pharmaceuticals, Inc. in July 2024. It operates from its headquarters in Baltimore, Maryland.